Inflammatory Bowel Disease (IBD) Drugs Market to Grow at 5.41% CAGR through 2029
Rising
prevalence of inflammatory bowel disease and increasing investment in Research
and Development is expected to drive the Global Inflammatory Bowel Disease
(IBD) Drugs Market growth in the forecast period, 2025-2029.
According to
TechSci Research report, “Inflammatory Bowel Disease (IBD) Drugs Market – Global
Industry Size, Share, Trends, Competition Forecast & Opportunities, 2019-2029F”,
the Global Inflammatory Bowel Disease (IBD) Drugs Market stood at USD 21.73 Billion in
2023 and is anticipated to project steady growth in the forecast period with a
CAGR of 5.41%
through 2029. Some
of the factors driving the overall market expansion include the rise in the
prevalence of Crohn's disease and ulcerative colitis, increasing disease
awareness around the world, and initiatives to discover treatments for
inflammatory bowel disease. Adalimumab, infliximab, certolizumab, and golimumab
are some of the medications used to treat inflammatory bowel disease, which is
driving the market's expansion overall.
Browse over XX
market data Figures spread through XX Pages and an in-depth TOC on
"Global Inflammatory Bowel Disease (IBD) Drugs Market”
Inflammatory
bowel disease is a chronic disease that affects the digestive tract, leading to
inflammation and damage. The development of new drugs for the treatment of IBD
is an ongoing process. Advances in drug research and development have resulted
in the development of newer and more effective drugs for the treatment of IBD.
These drugs target specific mechanisms in the body that are involved in the
development of IBD. The introduction of biologic therapies, such as anti-TNF
drugs, has revolutionized the treatment of IBD. Anti-TNF drugs are monoclonal
antibodies that target the tumor necrosis factor-alpha (TNF-alpha), a protein
involved in the immune system's response to inflammation. Anti-TNF drugs, such
as infliximab and adalimumab, have been shown to be effective in inducing and
maintaining remission in patients with IBD. The introduction of these drugs has
changed the treatment possibilities for IBD, and they have become a standard of
care in the management of the disease.
The aging
population is another driver of the inflammatory bowel disease drugs market.
The incidence of IBD is higher in older individuals, and the disease is often
more severe in older age group. The aging population is expected to increase in
the coming years, leading to an increase in the number of patients with IBD.
The cost of treatment for IBD can be high, and the disease is often chronic,
requiring long-term treatment, thus the introduction of biologic therapies has
significantly increased the cost of treatment for IBD. Biologics, a novel class
of medications, have become accessible in recent years for the treatment of
inflammatory bowel disease (IBD) and other inflammatory illnesses. These drugs
are expensive, and their high cost has been a barrier to access for many
patients. However, many pharmaceutical companies have their IBD drugs under
clinical trial which is expected to enter the market in the upcoming years
which is expected to be more affordable to the patients.
In the last two
decades, there have been major changes in the way inflammatory bowel disease
(IBD) is treated. The biologic era brought forth the idea of
"treat-to-target" approaches and changed the focus to therapies that
can reduce inflammation and alter the course of IBD.
Moreover,
increasing investment in the research and development of novel IDB drugs is
another factor which is growing the demand of IDB drugs. Brazikumab is an
investigational medication being investigated for inflammatory bowel disease
(IBD), and in 2018 Allergan plc announced the beginning of two global clinical
development programmes. Both the INTREPID (Crohn's disease) and EXPEDITION
(ulcerative colitis) studies will assess the Brazikumab's efficacy and safety,
and they will look into the function of biomarkers in predicting the
treatment's effectiveness in IBD patients. The first randomized comparison of
an IL-23 inhibitor versus HUMIRA® (adalimumab) in Crohn's disease and ENTYVIO®
(vedolizumab) in ulcerative colitis, as well as the first active comparison study
of an IL-23 inhibitor therapy in IBD to evaluate biomarkers as potential
predictors of treatment response is the main target of the study.
Following a
Phase 2 clinical trial that demonstrated improved anti-inflammatory response
and remission rates with Brazikumab in patients with Crohn's disease who had
higher levels of a key IBD biomarker compared to those who had lower levels,
Allergan is launching the INTREPID and EXPEDITION programmes. The Phase 2b/3,
multicenter, randomised, placebo- and active-controlled, parallel-group,
Crohn's disease programme INTREPID is patient-centered. Brazikumab will be
compared to a placebo plus HUMIRA® (adalimumab) in Stage 1 (Phase 2b) and to
HUMIRA® solely in Stage 2 (Phase 3). There will be about 450 patients enrolled in
Stage 1 and 690 patients enrolled in Stage 2. All study participants will have
access to study treatments after the trial. ENTYVIO® (vedolizumab) or a placebo
will be used to compare the safety and effectiveness of Brazikumab. There will
be 375 patients total enrolled. The program's anticipated Phase 3 component
will incorporate the biomarker knowledge gained from this study.
A
"stand-alone" biologics license application (BLA) for the lead
product candidate, CT-P13 SC, which is the subcutaneous formulation of
infliximab, was submitted to the U.S. Food and Drug Administration (FDA) in
2022, by Celltrion USA. The submission was based on findings from phase III
pivotal data that assessed CT-P13 SC's safety and efficacy in patients with
moderate to severe active ulcerative colitis (UC) and Crohn's disease (CD)
(LIBERTY-UC) and as maintenance therapy (LIBERTY-CD). According to the findings
of the LIBERTY-UC and LIBERTY-CD investigations, CT-P13 SC showed superiority
over placebo in maintenance therapy following induction therapy with
intravenous infliximab in patients with Ulcerative Colitis and Crohn’s Disease,
respectively, over a one-year treatment period.
The alarming
rise in chronic inflammatory bowel disorders, the rise in government measures
to boost the pharmaceutical sector, and the rise in the number of approvals for
ulcerative colitis medications are the key drivers of the expansion of the
inflammatory bowel disease drug market.
The Global Inflammatory
Bowel Disease (IBD) Drugs Market is segmented into drug class, disease indication, route of
administration, distribution channel,
regional distribution, and company.
Based on disease
indication, the ulcerative colitis segment is expected to show steady growth
during the forecast period. Due to the rising acceptance of biologics for the
treatment of ulcerative colitis and the large patient population of UC, the
ulcerative colitis market is predicted to grow at a profitable rate. The use of
biologic treatments to treat ulcerative colitis is anticipated to grow at a
profitable pace within the anticipated time frame. Pharmaceutical companies are
working together to provide the growing need for treatment medications for
ulcerative colitis. For instance, Athos Therapeutics announced their plan for a
research partnership with Lahey Hospital and Medical Centre in Burlington,
Massachusetts, in July 2022. The research partnership would focus on the
development of precision medicine for IBD and ulcerative colitis.
Based on route of
administration, the injectable segment is expected to dominate the global
inflammatory bowel disease drug market in the forecast year. Due to the high adoption
rate of biologics and biosimilar products, higher costs, quick onset of action,
and higher bioavailability of injectable medications, the injectable sector is
anticipated to have the greatest market share. The segment share has also
increased due to the broad availability of injectable medicines for the
treatment of IBD. For instance, the substantial market share of injectable
medications is supported by the higher prescription rate of injectable
formulations like Humira (adalimumab), Remicade (infliximab), Stelara
(ustekinumab), Cimzia (certolizumab), Entyvio (vedolizumab), and others.
Major companies
operating in Global Inflammatory Bowel Disease (IBD) Drugs Market
are:
- Takeda
Pharmaceutical Company Limited
- AbbVie
Inc.
- Pfizer
Inc.
- UCB
S.A.
- Johnson
& Johnson
- Novartis
AG
- Bristol
Myers Squibb Co.
- Merck
& Co., Inc.
- Celltrion,
Inc.
Download Free Sample Report
Customers can
also request for 10% free customization on this report
“As the
incidence of ulcerative colitis rises, so does the demand for treatments for
inflammatory bowel disease, which in turn is fueling the growth of the global
market. The global market is being supported by the growing preference for
biologic and biosimilar medications over conventional treatment alternatives
due to their increased efficacy. A favorable picture for the market is also
being created by the rising use of pre-biotic and pro-biotic food items to
enhance gut health. Additionally, the global market is being further expanded
by the ongoing development of innovative medicines with improved clinical
profiles and patient friendly RoAs (routes of administration). The inflammatory
bowel disease market is anticipated to be driven by several additional aspects
in the years to come, such as the growing use of single-cell RNA analysis to
comprehend the molecular foundation of the disease and the rising penetration
of targeted and sophisticated medicines.,” said Mr. Karan Chechi, Research
Director with TechSci Research, a research-based management consulting firm.
“Inflammatory Bowel Disease (IBD) Drugs Market - Global
Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Drug Class (TNF
Inhibitors, Corticosteroids, Amino Salicylates, Immunomodulators, Others), By
Disease Indication (Ulcerative Colitis, Crohn’s Disease), By Route of Administration (Oral, Injectable),
By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), By Region and Competition, 2019-2029F”,
has evaluated the future growth potential of Global Inflammatory Bowel Disease
(IBD) Drugs Market and provides statistics & information on market size,
structure and future market growth. The report intends to provide cutting-edge
market intelligence and help decision makers take sound investment decisions.
Besides, the report also identifies and analyzes the emerging trends along with
essential drivers, challenges, and opportunities in Global Inflammatory Bowel
Disease (IBD) Drugs Market.
Contact
TechSci
Research LLC
420
Lexington Avenue, Suite 300,
New York,
United States- 10170
Tel: +1-332-258-6602
Email: [email protected]
Website: www.techsciresearch.com